胶质母细胞瘤治疗抵抗的机制、微环境与模型解读
本文综述成人胶质母细胞瘤对放疗、化疗、靶向和免疫治疗抵抗的分子、细胞及解剖决定因素,强调瘤内与瘤间异质性、转录可塑性及适应重编程的作用,并评估现有临床前模型的优势与不足,最后提出克服抵抗的新策略。
要点
- 胶质母细胞瘤中位生存约16个月,几乎所有肿瘤复发。
- 抵抗涉及DNA损伤反应、缺氧龛、间质转化和免疫逃逸等机制。
- 现有临床前模型无法完全复现人胶质母细胞瘤的关键特征。
核心结论
- 胶质母细胞瘤的治疗抵抗由肿瘤内在机制、微环境限制和临床前模型局限性共同导致。
- 整合机制理解并采用合理联合治疗、适应性试验设计和生物标志物分层有望克服抵抗。
研究设计与样本
- 本文为综述,汇总成人胶质母细胞瘤对放疗、化疗、靶向治疗和免疫治疗抵抗的分子、细胞及解剖决定因素。
- 综述重点评估了已建细胞系、患者来源异种移植、同基因模型和基因工程小鼠模型在塑造治疗抵抗理解中的作用。
主要发现
- 广泛瘤内与瘤间异质性、转录可塑性和适应重编程使肿瘤细胞逃避细胞毒性应激。
- 关键抵抗机制包括DNA损伤反应通路激活、利用缺氧龛、治疗诱导的间质转化及通过抗原提呈受损和免疫抑制微环境逃避免疫监视。
- 胶质母细胞瘤利用中枢神经系统独特免疫特征(血脑屏障、有限抗原负荷、耐受性髓系细胞群)削弱免疫治疗疗效。
- 多数临床前有前景的疗法在随机临床试验中未能改善结局。
临床怎么用
- 临床应认识到胶质母细胞瘤治疗抵抗的多机制性,并关注合理联合治疗、适应性试验设计和生物标志物驱动分层等新兴策略。
局限性
- 现有临床前模型(细胞系、患者来源异种移植、同基因模型、基因工程小鼠模型)无法完全复现人胶质母细胞瘤的定义性特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glioblastoma (GBM) is the most common and lethal primary malignant brain tumor in adults. Despite aggressive multimodal therapy, including maximal safe resection, radiation therapy, and temozolomide chemotherapy, median survival remains approximately 16 months, and nearly all tumors recur. Over the past 2 decades, numerous therapies that demonstrated promise in preclinical studies have failed to improve outcomes in randomized clinical trials, underscoring the therapeutic resistance that defines this disease. This resistance arises from the convergence of tumor-intrinsic mechanisms, microenvironmental constraints, and limitations of current preclinical models. In this review, we synthesize advances in understanding the molecular, cellular, and anatomic determinants of resistance to radiation therapy, chemotherapy, targeted therapies, and immunotherapies in adult GBM. We highlight how extensive intra- and intertumoral heterogeneity, transcriptional plasticity, and adaptive reprogramming enable tumor cells to evade cytotoxic stress. Key resistance mechanisms include activation of DNA damage response pathways, exploitation of hypoxic niches, therapy-induced mesenchymal transitions, and evasion of immune surveillance through impaired antigen presentation and a profoundly immunosuppressive tumor microenvironment. We further discuss how GBM exploits the unique immunologic features of the central nervous system, including the blood-brain barrier, limited antigen burden, and tolerogenic myeloid populations, to blunt the efficacy of immunotherapies. A major focus of this review is the role of preclinical models in shaping our understanding of therapeutic resistance. We critically evaluate established cell lines, patient-derived xenografts, syngeneic models, and genetically engineered mouse models, emphasizing both their strengths and their inability to fully recapitulate defining features of human GBM. Finally, we outline emerging strategies to overcome resistance, including rational combination therapies, adaptive trial designs, improved biomarker-driven stratification, and integrative modeling approaches. Together, these insights provide a framework for translating mechanistic understanding into more effective, durable therapies for glioblastoma.
引用
- Wisdom AJ, Temple H, Cui Y, et al. Mechanisms, Microenvironments, and Models: Understanding Therapeutic Resistance in Glioblastoma. Int J Radiat Oncol Biol Phys. 2026. PMID: 42031225. doi:10.1016/j.ijrobp.2026.04.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。